BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xu X, Liu C, Wang Y, Koivisto O, Zhou J, Shu Y, Zhang H. Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment. Adv Drug Deliv Rev 2021;176:113891. [PMID: 34324887 DOI: 10.1016/j.addr.2021.113891] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang L, Liu C, Wang X, Ma S, Liu F, Zhang Y, Wang Y, Shen M, Wu X, Wu Q, Gong C. Tumor-specific activated nano-domino-CRISPR to amplify intrinsic oxidative and activate endogenous apoptosis for spatiotemporally specific therapy. Biomaterials 2023;295:122056. [PMID: 36805243 DOI: 10.1016/j.biomaterials.2023.122056] [Reference Citation Analysis]
2 Zhu X, Gao M, Yang Y, Li W, Bao J, Li Y. The CRISPR/Cas9 System Delivered by Extracellular Vesicles. Pharmaceutics 2023;15:984. [PMID: 36986843 DOI: 10.3390/pharmaceutics15030984] [Reference Citation Analysis]
3 Carneiro SP, Greco A, Chiesa E, Genta I, Merkel OM. Shaping the future from the small scale: dry powder inhalation of CRISPR-Cas9 lipid nanoparticles for the treatment of lung diseases. Expert Opin Drug Deliv 2023;:1-17. [PMID: 36896650 DOI: 10.1080/17425247.2023.2185220] [Reference Citation Analysis]
4 Zhang P, Xiao Y, Sun X, Lin X, Koo S, Yaremenko AV, Qin D, Kong N, Farokhzad OC, Tao W. Cancer nanomedicine toward clinical translation: Obstacles, opportunities, and future prospects. Med (N Y) 2023;4:147-67. [PMID: 36549297 DOI: 10.1016/j.medj.2022.12.001] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Ueda J, Yamazaki T, Funakoshi H. Toward the Development of Epigenome Editing-Based Therapeutics: Potentials and Challenges. Int J Mol Sci 2023;24. [PMID: 36902207 DOI: 10.3390/ijms24054778] [Reference Citation Analysis]
6 Meng X, Wu TG, Lou QY, Niu KY, Jiang L, Xiao QZ, Xu T, Zhang L. Optimization of CRISPR-Cas system for clinical cancer therapy. Bioeng Transl Med 2023;8:e10474. [PMID: 36925702 DOI: 10.1002/btm2.10474] [Reference Citation Analysis]
7 Hu X, Zhu H, He X, Chen J, Xiong L, Shen Y, Li J, Xu Y, Chen W, Liu X, Cao D, Xu X. The application of nanoparticles in immunotherapy for hepatocellular carcinoma. J Control Release 2023;355:85-108. [PMID: 36708880 DOI: 10.1016/j.jconrel.2023.01.051] [Reference Citation Analysis]
8 Aalhate M, Mahajan S, Singh H, Guru SK, Singh PK. Nanomedicine in therapeutic warfront against estrogen receptor-positive breast cancer. Drug Deliv Transl Res 2023. [PMID: 36795198 DOI: 10.1007/s13346-023-01299-7] [Reference Citation Analysis]
9 Pauna AR, Mititelu Tartau L, Bogdan M, Meca AD, Popa GE, Pelin AM, Drochioi CI, Pricop DA, Pavel LL. Synthesis, Characterization and Biocompatibility Evaluation of Novel Chitosan Lipid Micro-Systems for Modified Release of Diclofenac Sodium. Biomedicines 2023;11. [PMID: 36830989 DOI: 10.3390/biomedicines11020453] [Reference Citation Analysis]
10 Fang M, Zhang H, Wang Y, Zhang H, Zhang D, Xu P. Biomimetic selenium nanosystems for infectious wound healing. Engineered Regeneration 2023. [DOI: 10.1016/j.engreg.2023.01.004] [Reference Citation Analysis]
11 Aziz A, Rehman U, Sheikh A, Abourehab MAS, Kesharwani P. Lipid-based nanocarrier mediated CRISPR/Cas9 delivery for cancer therapy. J Biomater Sci Polym Ed 2023;34:398-418. [PMID: 36083788 DOI: 10.1080/09205063.2022.2121592] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Pu Y, Wu W, Xiang H, Chen Y, Xu H. CRISPR/Cas9-based genome editing for multimodal synergistic cancer nanotherapy. Nano Today 2023;48:101734. [DOI: 10.1016/j.nantod.2022.101734] [Reference Citation Analysis]
13 Li T, Yang Y, Qi H, Cui W, Zhang L, Fu X, He X, Liu M, Li PF, Yu T. CRISPR/Cas9 therapeutics: progress and prospects. Signal Transduct Target Ther 2023;8:36. [PMID: 36646687 DOI: 10.1038/s41392-023-01309-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Yan B, Liang Y. New Therapeutics for Extracellular Vesicles: Delivering CRISPR for Cancer Treatment. Int J Mol Sci 2022;23. [PMID: 36555398 DOI: 10.3390/ijms232415758] [Reference Citation Analysis]
15 Ahmad A, Gulraiz Y, Ilyas S, Bashir S. Polysaccharide based nano materials: Health implications. Food Hydrocolloids for Health 2022;2:100075. [DOI: 10.1016/j.fhfh.2022.100075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Coluccia M, Parisse V, Guglielmi P, Giannini G, Secci D. Metal-organic frameworks (MOFs) as biomolecules drug delivery systems for anticancer purposes. European Journal of Medicinal Chemistry 2022;244:114801. [DOI: 10.1016/j.ejmech.2022.114801] [Reference Citation Analysis]
17 Wang Y, Wang N, Yang Y, Chen Y, Zhang Z. Cellular nanomechanics derived from pattern-dependent focal adhesion and cytoskeleton to balance gene transfection of malignant osteosarcoma. J Nanobiotechnol 2022;20:499. [DOI: 10.1186/s12951-022-01713-1] [Reference Citation Analysis]
18 Cruz LJ, Rezaei S, Grosveld F, Philipsen S, Eich C. Nanoparticles targeting hematopoietic stem and progenitor cells: Multimodal carriers for the treatment of hematological diseases. Front Genome Ed 2022;4. [DOI: 10.3389/fgeed.2022.1030285] [Reference Citation Analysis]
19 Farheen J, Hosmane NS, Zhao R, Zhao Q, Iqbal MZ, Kong X. Nanomaterial-assisted CRISPR gene-engineering - A hallmark for triple-negative breast cancer therapeutics advancement. Mater Today Bio 2022;16:100450. [PMID: 36267139 DOI: 10.1016/j.mtbio.2022.100450] [Reference Citation Analysis]
20 Tseng S, Kempson IM, Liao Z, Ho Y, Yang P. An acid degradable, lactate oxidizing nanoparticle formulation for non-small cell lung cancer virotherapy. Nano Today 2022;46:101582. [DOI: 10.1016/j.nantod.2022.101582] [Reference Citation Analysis]
21 Kang K, Song Y, Kim I, Kim T. Therapeutic Applications of the CRISPR-Cas System. Bioengineering 2022;9:477. [DOI: 10.3390/bioengineering9090477] [Reference Citation Analysis]
22 Salman A, Kantor A, Mcclements ME, Marfany G, Trigueros S, Maclaren RE. Non-Viral Delivery of CRISPR/Cas Cargo to the Retina Using Nanoparticles: Current Possibilities, Challenges, and Limitations. Pharmaceutics 2022;14:1842. [DOI: 10.3390/pharmaceutics14091842] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Ashrafizadeh M, Aghamiri S, Tan SC, Zarrabi A, Sharifi E, Rabiee N, Kadumudi FB, Pirouz AD, Delfi M, Byrappa K, Thakur VK, Sharath Kumar KS, Girish YR, Zandsalimi F, Zare EN, Orive G, Tay F, Hushmandi K, Kumar AP, Karaman C, Karimi-maleh H, Mostafavi E, Makvandi P, Wang Y. Nanotechnological Approaches in Prostate Cancer Therapy: Integration of engineering and biology. Nano Today 2022;45:101532. [DOI: 10.1016/j.nantod.2022.101532] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
24 Tao S, Chen H, Li N, Liang W. The Application of the CRISPR-Cas System in Antibiotic Resistance. IDR 2022;Volume 15:4155-68. [DOI: 10.2147/idr.s370869] [Reference Citation Analysis]
25 Shen J, Liu C, Yan P, Wang M, Guo L, Liu S, Chen J, Rosenholm JM, Huang H, Wang R, Zhang H. Helper T Cell (CD4 + ) Targeted Tacrolimus Delivery Mediates Precise Suppression of Allogeneic Humoral Immunity. Research 2022;2022:1-15. [DOI: 10.34133/2022/9794235] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Tiwari S, Kaushik A. Nano-Neurogenesis for CNS Diseases and Disorders. Front Nanotechnol 2022;4. [DOI: 10.3389/fnano.2022.931259] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
27 Ahmed T, Liu FF, Lu B, Lip H, Park E, Alradwan I, Liu JF, He C, Zetrini A, Zhang T, Ghavaminejad A, Rauth AM, Henderson JT, Wu XY. Advances in Nanomedicine Design: Multidisciplinary Strategies for Unmet Medical Needs. Mol Pharm 2022. [PMID: 35587783 DOI: 10.1021/acs.molpharmaceut.2c00038] [Reference Citation Analysis]
28 Crintea A, Dutu AG, Sovrea A, Constantin AM, Samasca G, Masalar AL, Ifju B, Linga E, Neamti L, Tranca RA, Fekete Z, Silaghi CN, Craciun AM. Nanocarriers for Drug Delivery: An Overview with Emphasis on Vitamin D and K Transportation. Nanomaterials (Basel) 2022;12:1376. [PMID: 35458084 DOI: 10.3390/nano12081376] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Wang S, Gao C, Zheng Y, Yi L, Lu J, Huang X, Cai J, Zhang P, Cui Y, Ke A. Current applications and future perspective of CRISPR/Cas9 gene editing in cancer. Mol Cancer 2022;21. [DOI: 10.1186/s12943-022-01518-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
30 Yadav D, Kwak M, Chauhan PS, Puranik N, Lee PCW, Jin JO. Cancer immunotherapy by immune checkpoint blockade and its advanced application using bio-nanomaterials. Semin Cancer Biol 2022:S1044-579X(22)00044-X. [PMID: 35181474 DOI: 10.1016/j.semcancer.2022.02.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
31 Zhang C, Zhou X, Zhang H, Han X, Li B, Yang R, Zhou X. Recent Progress of Novel Nanotechnology Challenging the Multidrug Resistance of Cancer. Front Pharmacol 2022;13:776895. [DOI: 10.3389/fphar.2022.776895] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
32 Dubey AK, Kumar Gupta V, Kujawska M, Orive G, Kim N, Li C, Kumar Mishra Y, Kaushik A. Exploring nano-enabled CRISPR-Cas-powered strategies for efficient diagnostics and treatment of infectious diseases. J Nanostruct Chem. [DOI: 10.1007/s40097-022-00472-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
33 Mundekkad D, Cho WC. Nanoparticles in Clinical Translation for Cancer Therapy. Int J Mol Sci 2022;23:1685. [PMID: 35163607 DOI: 10.3390/ijms23031685] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 21.0] [Reference Citation Analysis]
34 Yan Y, Zhu X, Yu Y, Li C, Zhang Z, Wang F. Nanotechnology Strategies for Plant Genetic Engineering. Adv Mater 2022;34:e2106945. [PMID: 34699644 DOI: 10.1002/adma.202106945] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
35 Sohail M, Xie S, Zhang X, Li B. Methodologies in visualizing the activation of CRISPR/Cas: The last mile in developing CRISPR-Based diagnostics and biosensing – A review. Analytica Chimica Acta 2022. [DOI: 10.1016/j.aca.2022.339541] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
36 Jacob EM, Borah A, Sakthi Kumar D. CRISPR/Cas9 Nano-delivery Approaches for Targeted Gene Therapy. Nanotechnology in the Life Sciences 2022. [DOI: 10.1007/978-3-031-12658-1_2] [Reference Citation Analysis]
37 Bakrania A, Zheng G, Bhat M. Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment. Pharmaceutics 2021;14:41. [PMID: 35056937 DOI: 10.3390/pharmaceutics14010041] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
38 Cai L, Xu D, Chen H, Wang L, Zhao Y. Designing bioactive micro-/nanomotors for engineered regeneration. Engineered Regeneration 2021;2:109-15. [DOI: 10.1016/j.engreg.2021.09.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 12.5] [Reference Citation Analysis]
39 Yu Y, Wang Q, Wang C, Shang L. Living Materials for Regenerative Medicine. Engineered Regeneration 2021;2:96-104. [DOI: 10.1016/j.engreg.2021.08.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 10.0] [Reference Citation Analysis]